72 related articles for article (PubMed ID: 14761607)
1. [Topoisomerase II inhibitors etoposide and doxorubicin induced rearrangement and fusion of AML1 gene].
Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2003 Dec; 24(12):621-3. PubMed ID: 14761607
[TBL] [Abstract][Full Text] [Related]
2. Cryptic chromosomal aberrations leading to an AML1/ETO rearrangement are frequently caused by small insertions.
Gamerdinger U; Teigler-Schlegel A; Pils S; Bruch J; Viehmann S; Keller M; Jauch A; Harbott J
Genes Chromosomes Cancer; 2003 Mar; 36(3):261-72. PubMed ID: 12557226
[TBL] [Abstract][Full Text] [Related]
3. A novel gene, FGA7, is fused to RUNX1/AML1 in a t(4;21)(q28;q22) in a patient with T-cell acute lymphoblastic leukemia.
Mikhail FM; Coignet L; Hatem N; Mourad ZI; Farawela HM; El Kaffash DM; Farahat N; Nucifora G
Genes Chromosomes Cancer; 2004 Feb; 39(2):110-8. PubMed ID: 14695990
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of 21 children with acute non-lymphoid leukemia carrying AML1/ETO fusion gene].
Zhao W; Li ZG; Wu MY; Geng LZ; Shi HW; Zhang YH; Wu RH
Zhonghua Er Ke Za Zhi; 2003 May; 41(5):325-8. PubMed ID: 14751048
[TBL] [Abstract][Full Text] [Related]
5. Leukemogenic AML1-ETO fusion protein increases carcinogen-DNA adduct formation with upregulated expression of cytochrome P450-1A1 gene.
Xu M; Li D; Lu Y; Chen GQ
Exp Hematol; 2007 Aug; 35(8):1249-55. PubMed ID: 17560011
[TBL] [Abstract][Full Text] [Related]
6. Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement.
Viehmann S; Teigler-Schlegel A; Bruch J; Langebrake C; Reinhardt D; Harbott J
Leukemia; 2003 Jun; 17(6):1130-6. PubMed ID: 12764380
[TBL] [Abstract][Full Text] [Related]
7. Repositioning of ETO gene in cells treated with VP-16, an inhibitor of DNA-topoisomerase II.
Rubtsov MA; Terekhov SM; Razin SV; Iarovaia OV
J Cell Biochem; 2008 May; 104(2):692-9. PubMed ID: 18183572
[TBL] [Abstract][Full Text] [Related]
8. Rearrangements of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: in vitro and in vivo studies.
Zent C; Rowley JD; Nucifora G
Leukemia; 1997 Apr; 11 Suppl 3():273-8. PubMed ID: 9209363
[TBL] [Abstract][Full Text] [Related]
9. High incidence of TEL/AML1 fusion resulting from a cryptic t(12;21) in childhood B-lineage acute lymphoblastic leukemia in Taiwan.
Liang DC; Chou TB; Chen JS; Shurtleff SA; Rubnitz JE; Downing JR; Pui CH; Shih LY
Leukemia; 1996 Jun; 10(6):991-3. PubMed ID: 8667657
[TBL] [Abstract][Full Text] [Related]
10. Molecular diversity in AML1/ETO fusion transcripts in patients with t(8;21) positive acute myeloid leukaemia.
van de Locht LT; Smetsers TF; Wittebol S; Raymakers RA; Mensink EJ
Leukemia; 1994 Oct; 8(10):1780-4. PubMed ID: 7523801
[TBL] [Abstract][Full Text] [Related]
11. NHR4 domain mutations of ETO are probably very infrequent in AML1-ETO positive myeloid leukemia cells.
Hackanson B; Abdelkarim M; Jansen JH; Lübbert M
Leukemia; 2010 Apr; 24(4):860-1. PubMed ID: 20090777
[No Abstract] [Full Text] [Related]
12. PRDX4, a member of the peroxiredoxin family, is fused to AML1 (RUNX1) in an acute myeloid leukemia patient with a t(X;21)(p22;q22).
Zhang Y; Emmanuel N; Kamboj G; Chen J; Shurafa M; Van Dyke DL; Wiktor A; Rowley JD
Genes Chromosomes Cancer; 2004 Aug; 40(4):365-70. PubMed ID: 15188461
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of DNA topoisomerase II with etoposide induces association of DNA topoisomerase II alpha, DNA topoisomerase II beta, and nucleolin with BCR 2 of the ETO gene.
Rubtsov MA; Razin SV; Iarovaia OV
Dokl Biochem Biophys; 2008; 423():334-6. PubMed ID: 19230382
[No Abstract] [Full Text] [Related]
14. Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia.
Stams WA; den Boer ML; Beverloo HB; Meijerink JP; van Wering ER; Janka-Schaub GE; Pieters R
Clin Cancer Res; 2005 Apr; 11(8):2974-80. PubMed ID: 15837750
[TBL] [Abstract][Full Text] [Related]
15. AML1 and AML1 fusion protein AML1-ETO in myeloid gene regulation and leukemogenesis.
Zhang DE; Burel S; Zhou L; Hetherington CJ; Yuan Y
Blood Cells Mol Dis; 2001; 27(2):368-76. PubMed ID: 11259158
[No Abstract] [Full Text] [Related]
16. Epigenetic Silencing of Eyes Absent 4 Gene by Acute Myeloid Leukemia 1-Eight-twenty-one Oncoprotein Contributes to Leukemogenesis in t(8;21) Acute Myeloid Leukemia.
Huang S; Jiang MM; Chen GF; Qian K; Gao HH; Guan W; Shi JL; Liu AQ; Liu J; Wang BH; Li YH; Yu L
Chin Med J (Engl); 2016 Jun; 129(11):1355-62. PubMed ID: 27231175
[TBL] [Abstract][Full Text] [Related]
17. The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1.
Frank RC; Sun X; Berguido FJ; Jakubowiak A; Nimer SD
Oncogene; 1999 Mar; 18(9):1701-10. PubMed ID: 10208431
[TBL] [Abstract][Full Text] [Related]
18. Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO.
Fliegauf M; Stock M; Berg T; Lübbert M
Oncogene; 2004 Dec; 23(56):9070-81. PubMed ID: 15489901
[TBL] [Abstract][Full Text] [Related]
19. PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoter.
Tabe Y; Konopleva M; Kondo Y; Contractor R; Jin L; Ruvolo V; Tsutsumi-Ishii Y; Miyake K; Miyake N; Ohsaka A; Nagaoka I; Issa JP; Andreeff M
Ann Hematol; 2006 Oct; 85(10):689-704. PubMed ID: 16832676
[TBL] [Abstract][Full Text] [Related]
20. Identical fusion transcript associated with different breakpoints in the AML1 gene in simple and variant t(8;21) acute myeloid leukemia.
de Greef GE; Hagemeijer A; Morgan R; Wijsman J; Hoefsloot LH; Sandberg AA; Sacchi N
Leukemia; 1995 Feb; 9(2):282-7. PubMed ID: 7869765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
